Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology is well-positioned for success in the near-term with their upcoming Ph. 3 PIVOT-006 topline data and the completion of their initial HR BCG-UR NMIBC BLA in 4Q. They have a strong cash position to fund their operations through 2029, and their unique and effective approach to treating bladder cancer gives them a competitive advantage in the market. Additionally, their pipeline of clinical programs for cretostimogene has the potential to further broaden addressable market opportunities and drive future growth.

Bears say

CG Oncology is facing challenges with delay in its PIVOT-006 trial and potential competition from other players in the market, putting pressure on its stock. With the potential for additional equity financing, there is a risk for dilution and negative impact on share price. Additionally, the success of CG Oncology's drug candidate may hinge on specific factors such as durability thresholds and treatment schedule preference, and any delays in approval could negatively impact the company's stock price. Furthermore, the company may face stiff competition from other companies with greater resources.

CGON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 10 analysts, CGON has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.